Rapport Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Rapport Therapeutics, Inc. (RAPP) reported Increase (Decrease) in Accounts Receivable of $293.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- Rapport Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $235.00K.
- Rapport Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $58.00K.
- Rapport Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $0.00.
- Rapport Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month |
|---|---|---|
| 2026-06-30 | $235.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $293.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $58.00K 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |